Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on ground-breaking research from the MRC Weatherall Institute of Molecular Medicine at University of Oxford.

Conceptual illustration of targetted cell therapy © ArtemisDiana/Shutterstock

Supported by Oxford University Innovation, the company will leverage over two decades of work by co-founder Professor Paresh Vyas to target common cancer proteins and revolutionise treatment options for patients.

The company secured a £16.5 million Series A funding round, led by the investment management firm Syncona Limited, which will drive the development of innovative treatments targeting specific cancer markers.

Over the past 20 years, working in the MRC Molecular Haematology, Professor Vyas has compiled a unique biobank of over 10,000 samples from more than 3,000 acute myeloid leukaemia (AML) patients, including those cured through blood cell transplants. This extensive research has led to the discovery of new cancer markers that could enable highly targeted treatments.

Read the full story on the MRC Weatherall Institute of Molecular Medicine website